A pathophysiology-based approach to the diagnosis and treatment of lupus nephritis

Kidney International

Volumn 90, Issue 3, 2016, Pages 493-501

  Anders, Hans Joachim ^a   Rovin, Brad ^b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

autoimmunity; disease activity; immune complex; proteinuria; trial design

Indexed keywords

ABATACEPT; ALPHA INTERFERON; ANIFROLUMAB; AZATHIOPRINE; BELIMUMAB; CD11B ANTIGEN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; KIDNEY INJURY MOLECULE 1; LAQUINIMOD; MONOCYTE CHEMOTACTIC PROTEIN 1; MYCOPHENOLATE MOFETIL; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 9; ANTINUCLEAR ANTIBODY; BIOLOGICAL MARKER; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; MEMBRANE PROTEIN; NEPHRIN;

ANTIBODY PRODUCTION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; DISEASE ACTIVITY; DISEASE CLASSIFICATION; DRUG DOSE COMPARISON; DRUG MEGADOSE; GENE FUNCTION; GENETIC HETEROGENEITY; GENETIC RISK; GLOMERULONEPHRITIS; GLOMERULUS FILTRATION RATE; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; KIDNEY BIOPSY; LOW DRUG DOSE; LUPUS ERYTHEMATOSUS NEPHRITIS; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT DURATION; TREATMENT RESPONSE; AUTOIMMUNITY; BIOPSY; CLINICAL TRIAL (TOPIC); GENETIC PREDISPOSITION; GENETICS; IMMUNOLOGY; KIDNEY; LUPUS NEPHRITIS; MUTATION; PATHOLOGY; PROTEINURIA; URINE;

ANTIBODIES, ANTINUCLEAR; AUTOIMMUNITY; BIOMARKERS; BIOPSY; CLINICAL TRIALS AS TOPIC; GENETIC PREDISPOSITION TO DISEASE; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; LUPUS NEPHRITIS; MEMBRANE PROTEINS; MUTATION; PROTEINURIA;

EID: 84994336868     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1016/j.kint.2016.05.017     Document Type: Review

References (54)

1. 1 Hanly, J.G., O'Keeffe, A.G., Su, L., et al. The frequency and outcome of lupus nephritis: results from an international inception cohort study. Rheumatology (Oxford) 55:2 (2016), 252–262.
2. 2 Goodnow, C.C., Multistep pathogenesis of autoimmune disease. Cell 130:1 (2007), 25–35.
3. 3 Lech, M., Anders, H.J., The pathogenesis of lupus nephritis. J Am Soc Nephrol 24:9 (2013), 1357–1366.
4. 4 Ghodke-Puranik, Y., Niewold, T.B., Immunogenetics of systemic lupus erythematosus: a comprehensive review. J Autoimmun 64 (2015), 125–136.
5. 5 Aggarwal, R., Sestak, A.L., D'Sousa, A., et al. Complete complement deficiency in a large cohort of familial systemic lupus erythematosus. Lupus 19:1 (2010), 52–57.
6. 6 Crow, Y.J., Manel, N., Aicardi-Goutieres syndrome and the type I interferonopathies. Nat Rev Immunol 15:7 (2015), 429–440.
7. 7 Rahman, A., Isenberg, D.A., Systemic lupus erythematosus. N Engl J Med 358:9 (2008), 929–939.
8. 8 Hiepe, F., Dörner, T., Hauser, A.E., et al. Long-lived autoreactive plasma cells drive persistent autoimmune inflammation. Nat Rev Rheumatol 7:3 (2011), 170–178.
9. 9 Cornaby, C., Gibbons, L., Mayhew, V., et al. B cell epitope spreading: mechanisms and contribution to autoimmune diseases. Immunol Lett 163:1 (2015), 56–68.
10. 10 Anders, H.J., Pseudoviral immunity - a novel concept for lupus. Trends Mol Med 15:12 (2009), 553–561.
11. 11 Patole, P.S., Zecher, D., Pawar, R.D., et al. G-rich DNA suppresses systemic lupus. J Am Soc Nephrol 16:11 (2005), 3273–3280.
12. 12 Pawar, R.D., Ramanjaneyulu, A., Kulkarni, O.P., et al. Inhibition of Toll-like receptor-7 (TLR-7) or TLR-7 plus TLR-9 attenuates glomerulonephritis and lung injury in experimental lupus. J Am Soc Nephrol 18:6 (2007), 1721–1731.
13. 13 Migliorini, A., Anders, H.J., A novel pathogenetic concept-antiviral immunity in lupus nephritis. Nat Rev Nephrol 8:3 (2012), 183–189.
14. 14 Chung, S.A., Brown, E.E., Williams, A.H., et al. Lupus nephritis susceptibility loci in women with systemic lupus erythematosus. J Am Soc Nephrol 25:12 (2014), 2859–2870.
15. 15 Anders, H.J., Fogo, A.B., Immunopathology of lupus nephritis. Semin Immunopathol 36:4 (2014), 443–459.
16. 16 Freedman, B.I., Langefeld, C.D., Andringa, K.K., et al. End-stage renal disease in African Americans with lupus nephritis is associated with APOL1. Arthritis Rheumatol 66:2 (2014), 390–396.
17. 17 Chang, A., Henderson, S.G., Brandt, D., et al. In situ B cell-mediated immune responses and tubulointerstitial inflammation in human lupus nephritis. J Immunol 186:3 (2011), 1849–1860.
18. 18 Allam, R., Anders, H.J., The role of innate immunity in autoimmune tissue injury. Curr Opin Rheumatol 20:5 (2008), 538–544.
19. 19 Kurts, C., Panzer, U., Anders, H.-J., et al. The immune system and kidney disease: basic concepts and clinical implications. Nat Rev Immunol 13:10 (2013), 738–753.
20. 20 Weening, J.J., D'Agati, V.D., Schwartz, M.M., et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 15:2 (2004), 241–250.
21. 21 Anders, H.J., Weening, J.J., Kidney disease in lupus is not always 'lupus nephritis'. Arthritis Res Ther, 15(2), 2013, 108.
22. 22 Song, D., Wu, L.H., Wang, F.M., et al. The spectrum of renal thrombotic microangiopathy in lupus nephritis. Arthritis Res Ther, 15(1), 2013, R12.
23. 23 Romagnani P, Giglio S, Angelotti ML, et al. Next generation sequencing and functional analysis of patient urine renal progenitor-derived podocytes to unravel the diagnosis underlying refractory lupus nephritis. Nephrol Dial Trans, in press.
24. 24 Vivante, A., Hildebrandt, F., Exploring the genetic basis of early-onset chronic kidney disease. Nat Rev Nephrol 12:3 (2016), 133–146.
25. 25 Anders, H.J., Jayne, D.R., Rovin, B.H., Hurdles to the introduction of new therapies for immune-mediated kidney diseases. Nat Rev Nephrol 12:4 (2016), 205–216.
26. 26 Malvar, A., Pirruccio, P., Lococo, B., et al. Histologic versus clinical remission in proliferative lupus nephritis. [e-pub ahead of print] Nephrol Dial Transplant, 2015;Aug 6 pii: gfv296, accessed May 29, 2016.
27. 27 Zickert, A., Sundelin, B., Svenungsson, E., Gunnarsson, I., Role of early repeated renal biopsies in lupus nephritis. Lupus Sci Med, 1(1), 2014, e000018.
28. 28 Alvarado, A.S., Malvar, A., Lococo, B., et al. The value of repeat kidney biopsy in quiescent Argentinian lupus nephritis patients. Lupus 23:8 (2014), 840–847.
29. 29 Kopetschke, K., Klocke, J., Grießbach, A.-S., et al. The cellular signature of urinary immune cells in Lupus nephritis: new insights into potential biomarkers. Arthritis Res Ther, 17, 2015, 94.
30. 30 Brunner, H.I., Bennett, M.R., Mina, R., et al. Association of noninvasively measured renal protein biomarkers with histologic features of lupus nephritis. Arthritis Rheum 64:8 (2012), 2687–2697.
31. 31 Brunner HI, Bennett MR, Abulaban K, et al. Development of a novel renal activity index of lupus nephritis in children & young adults [e-pub ahead of print]. Arthritis Care Res (Hoboken). http://dx.doi.org/10.1002/acr.22762, accessed May 29, 2016.
32. 32 Alsuwaida, A., Husain, S., Alghonaim, M., et al. Strategy for second kidney biopsy in patients with lupus nephritis. Nephrol Dial Transplant 27 (2012), 1472–1478.
33. 33 Kidney Disease Improving Global Outcomes (KDIGO). KDIGO Clinical Practice Guidelines for Glomerulonephritis. Kidney Int(suppl 2), 2012, 139–274.
34. 34 Rovin, B.H., Stillman, I.E., The kidney in systemic lupus erythematosus. Lahita, R.G., (eds.) Systemic Lupus Erythematosus, 2011, Academic Press, London, 769–814.
35. 35 Wofsy, D., Hillson, J.L., Diamond, B., Abatacept for lupus nephritis: alternative definitions of complete response support conflicting conclusions. Arthritis Rheum 64:11 (2012), 3660–3665.
36. 36 Furie, R., Nicholls, K., Cheng, T.T., et al. Efficacy and safety of abatacept in lupus nephritis: a twelve-month randomized, double-blind study. Arthritis Rheumatol 66 (2014), 379–389.
37. 37 Dall'Era, M., Cisternas, M.G., Smilek, D.E., et al. Predictors of long-term renal outcome in lupus nephritis trials: lessons learned from the Euro-Lupus Nephritis cohort. Arthritis Rheumatol 67:5 (2015), 1305–1313.
38. 38 Tamirou, F., Lauwerys, B.R., Dall'Era, M., et al. A proteinuria cut-off level of 0.7 g/day after 12 months of treatment best predicts long-term renal outcome in lupus nephritis: data from the MAINTAIN Nephritis Trial. Lupus Sci Med, 2(1), 2015, e000123.
39. 39 Houssiau, F.A., Vasconcelos, C., D'Cruz, D., et al. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 46:8 (2002), 2121–2131.
40. 40 Rovin, B.H., Parikh, S.V., Lupus nephritis: the evolving role of novel therapeutics. Am J Kidney Dis 63:4 (2014), 677–690.
41. 41 Maroz, N., Segal, M.S., Lupus nephritis and end-stage kidney disease. Am J Med Sci 346:4 (2013), 319–323.
42. 42 Henderson, L., Masson, P., Craig, J.C., et al. Treatment for lupus nephritis. Cochrane Database Syst Rev, 12, 2012, CD002922.
43. 43 Lourenco, E.V., Wong, M., Hahn, B.C., et al. Laquinimod delays and suppresses nephritis in lupus-prone mice and affects both myeloid and lymphoid immune cells. Arthritis Rheumatol 66 (2014), 674–685.
44. 44 Jayne, D., Appel, G.B., Chan, D.T.M., et al. The Pharmacokinetics of Laquinimod and Mycophenolate Mofetil during Treatment of Active Lupus Nephritis. 2013, American Society of Nephrology Annual Meeting, Atlanta.
45. 45 Manzi, S., Sánchez-Guerrero, J., Merrill, J.T., et al. Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials. Ann Rheum Dis 71:11 (2012), 1833–1838.
46. 46 Dooley, M.A., Houssiau, F., Aranow, C., et al. Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE. Lupus 22:1 (2013), 63–72.
47. 47 Group AT. Treatment of lupus nephritis with abatacept: the abatacept and cyclophosphamide combination efficacy and safety study. Arthritis Rheumatol 66:11 (2014), 3096–3104.
48. 48 Furie, R., Merrill, J., Werth, V., et al. Anifrolumab, an anti-interferon alpha receptor monoclonal antibody, in moderate to severe systemic lupus erythematosus. Am Coll Rheumatol, 67(suppl 10), 2015 [abstract].
49. 49 Hainz, N., Thomas, S., Neubert, K., et al. The proteasome inhibitor bortezomib prevents lupus nephritis in the NZB/W F1 mouse model by preservation of glomerular and tubulointerstitial architecture. Nephron Exp Nephrol 120:2 (2012), e47–e58.
50. 50 Neubert, K., Meister, S., Moser, K., et al. The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Nat Med 14:7 (2008), 748–755.
51. 51 Seavey, M.M., Lu, L.D., Stump, K.L., et al. Novel, orally active, proteasome inhibitor, delanzomib (CEP-18770), ameliorates disease symptoms and glomerulonephritis in two preclinical mouse models of SLE. Int Immunopharmacol 12:1 (2012), 257–270.
52. 52 Jansen, N.J., van Oeveren, W., van Vliet, M., et al. The role of different types of corticosteroids on the inflammatory mediators in cardiopulmonary bypass. Eur J Cardiothorac Surg 5:4 (1991), 211–217.
53. 53 Singh, A., Ghosh, R., Kaur, P., et al. Protocol renal biopsy in patients with lupus nephritis: a single center experience. Saudi J Kidney Dis Transpl 25:4 (2014), 801–807.
54. 54 Anders, H.J., Weidenbusch, M., Rovin, B., Unmet medical needs in lupus nephritis: solutions through evidence-based, personalized medicine. Clin Kidney J 8:5 (2015), 492–502.